r-n-jРоссийский неврологический журналRussian neurological journal2658-79472686-7192МИА10.30629/2658-7947-2025-30-6-4-10r-n-j-771Research ArticleОБЗОРЫREVIEWSИнсулинорезистентность и ишемический инсультInsulin resistance and ischemic strokehttps://orcid.org/0000-0002-7465-0677ПизоваН. В.PizovaN. V.

Ярославль

Yaroslavl

pizova@yandex.ruhttps://orcid.org/0000-0002-0522-675XПизовА. В.PizovA. V.

Ярославль

Yaroslavl

Ярославский государственный медицинский университетРоссияYaroslavl State Medical UniversityRussian FederationЯрославский государственный педагогический университет им. К.Д. УшинскогоРоссияYaroslavl State Pedagogical University named after K.D. UshinskyRussian Federation202512022026306410Copyright © Пизова Н.В., Пизов А.В., 20262026Пизова Н.В., Пизов А.В.Pizova N.V., Pizov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.r-n-j.com/jour/article/view/771

   Инсулинорезистентность является самостоятельным фактором риска развития ишемического инсульта (ИИ). Инсулинорезистентность способствует тромбообразованию и развитию атеросклероза, участвуя в основных патогенетических звеньях развития ИИ. Резистентность к инсулину также связана с некоторыми независимыми факторами риска инсульта, такими как гипертензия, гипертриглицеридемия и снижение уровня липопротеинов высокой плотности. Инсулинорезистентность негативно влияет на функциональное восстановление и прогноз у пациентов с ИИ независимо от того, есть ли у пациента сахарный диабет, но механизмы этого недостаточно изучены. Терапия инсулинорезистентности является важным компонентом вторичной профилактики ИИ и включает немедикаментозное и фармакологическое лечение. Представлены терапевтические подходы к инсулинорезистентности, которые позволяют предложить новые терапевтические направления для клинического улучшения прогноза у пациентов с ИИ.

   Insulin resistance is an independent risk factor for ischemic stroke (IS). Insulin resistance contributes to thrombus formation and atherosclerosis development, participating in the main pathogenetic links of IS. Insulin resistance is also associated with some independent risk factors for stroke, such as hypertension, hypertriglyceridemia, and low levels of high-density lipoprotein. Insulin resistance negatively aff ects functional recovery and prognosis in patients with IS, regardless of whether the patient has diabetes, but the mechanisms behind this are not well understood. Insulin resistance therapy is an important component of secondary prevention of IS and includes non-pharmacological and pharmacological treatment. The article presents therapeutic approaches to insulin resistance, which allow for the development of new therapeutic strategies to improve the clinical prognosis of patients with IS.

инсулинорезистентностьинсулиновая сигнализация в мозгеишемический инсульт.insulin resistanceinsulin signaling in the brainischemic strokeИсследование выполнено без финансовой поддержкиThe study was carried out without financial supportReferencesDiseases GBD, Injuries C. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–61. doi: 10.1016/S0140-6736(24)00757-8Diseases GBD, Injuries C. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–61. doi: 10.1016/S0140-6736(24)00757-8Agrawal R, Reno CM, Sharma S, Christensen C, Huang Y, Fisher SJ. Insulin action in the brain regulates both central and peripheral functions. Am J Physiol Endocrinol Metab. 2021;321(1):E156–e63. doi: 10.1152/ajpendo.00642.2020Agrawal R, Reno CM, Sharma S, Christensen C, Huang Y, Fisher SJ. Insulin action in the brain regulates both central and peripheral functions. Am J Physiol Endocrinol Metab. 2021;321(1):E156–e63. doi: 10.1152/ajpendo.00642.2020Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453–458. doi: 10.1172/JCI10762Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453–458. doi: 10.1172/JCI10762Deng XL, Liu Z, Wang C, Li Y, Cai Z. Insulin resistance in ischemic stroke. Metab Brain Dis. 2017;32(5):1323–1334. doi: 10.1007/s11011-017-0050-0Deng XL, Liu Z, Wang C, Li Y, Cai Z. Insulin resistance in ischemic stroke. Metab Brain Dis. 2017;32(5):1323–1334. doi: 10.1007/s11011-017-0050-0Ago T, Matsuo R, Hata J, Wakisaka Y, Kuroda J, Kitazono T, Kamouchi M, Fukuoka Stroke Registry Investigators. Insulin resistance and clinical outcomes after acute ischemic stroke. Neurology. 2018;90(17):e1470–e7. doi: 10.1212/WNL.0000000000005358Ago T, Matsuo R, Hata J, Wakisaka Y, Kuroda J, Kitazono T, Kamouchi M, Fukuoka Stroke Registry Investigators. Insulin resistance and clinical outcomes after acute ischemic stroke. Neurology. 2018;90(17):e1470–e7. doi: 10.1212/WNL.0000000000005358Rehni AK, Cho S, Dave KR. Ischemic brain injury in diabetes and endoplasmic reticulum stress. Neurochem Int. 2022;152:105219. doi: 10.1016/j.neuint.2021.105219Rehni AK, Cho S, Dave KR. Ischemic brain injury in diabetes and endoplasmic reticulum stress. Neurochem Int. 2022;152:105219. doi: 10.1016/j.neuint.2021.105219Kullmann S, Kleinridders A, Small DM, Fritsche A, Häring H-U, Preissl H, Heni M. Central nervous pathways of insulin action in the control of metabolism and food intake. Lancet Diabetes Endocrinol. 2020;8(6):524–34. doi: 10.1016/S2213-8587(20)30113-3Kullmann S, Kleinridders A, Small DM, Fritsche A, Häring H-U, Preissl H, Heni M. Central nervous pathways of insulin action in the control of metabolism and food intake. Lancet Diabetes Endocrinol. 2020;8(6):524–34. doi: 10.1016/S2213-8587(20)30113-3Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: Insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022;7(1):216. doi: 10.1038/s41392-022-01073-0Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: Insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022;7(1):216. doi: 10.1038/s41392-022-01073-0Dienel GA. Brain glucose metabolism: Integration of energetics with function. Physiol Rev. 2018;99(1):949–1045. doi: 10.1152/physrev.00062.2017Dienel GA. Brain glucose metabolism: Integration of energetics with function. Physiol Rev. 2018;99(1):949–1045. doi: 10.1152/physrev.00062.2017Magistretti PJ, Allaman I. Lactate in the brain: From metabolic end-product to signalling molecule. Nat Rev Neurosci. 2018;19(4):235–49. doi: 10.1038/nrn.2018.19Magistretti PJ, Allaman I. Lactate in the brain: From metabolic end-product to signalling molecule. Nat Rev Neurosci. 2018;19(4):235–49. doi: 10.1038/nrn.2018.19Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mithieux G, Moreira PI, Murphy MP, Nave K-A, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Swerdlow RH, Millan MJ. Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19(9):609–33. doi: 10.1038/s41573-020-0072-xCunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mithieux G, Moreira PI, Murphy MP, Nave K-A, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Swerdlow RH, Millan MJ. Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19(9):609–33. doi: 10.1038/s41573-020-0072-xHuang S, Czech MP. The Glut4 glucose transporter. Cell Metab. 2007;5(4):237–52. doi: 10.1016/j.cmet.2007.03.006Huang S, Czech MP. The Glut4 glucose transporter. Cell Metab. 2007;5(4):237–52. doi: 10.1016/j.cmet.2007.03.006Ashrafi G, Wu Z, Farrell RJ, Ryan TA. Glut4 mobilization supports energetic demands of active synapses. Neuron. 2017;93(3):606–15.e3. doi: 10.1016/j.neuron.2016.12.020Ashrafi G, Wu Z, Farrell RJ, Ryan TA. Glut4 mobilization supports energetic demands of active synapses. Neuron. 2017;93(3):606–15.e3. doi: 10.1016/j.neuron.2016.12.020Scherer T, Sakamoto K, Buettner C. Brain insulin signalling in metabolic homeostasis and disease. Nat Rev Endocrinol. 2021;17(8):468–83. doi: 10.1038/s41574-021-00498-xScherer T, Sakamoto K, Buettner C. Brain insulin signalling in metabolic homeostasis and disease. Nat Rev Endocrinol. 2021;17(8):468–83. doi: 10.1038/s41574-021-00498-xTalbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in alzheimer’s disease patients is associated with igf-1 resistance, irs-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–38. doi: 10.1172/JCI59903Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in alzheimer’s disease patients is associated with igf-1 resistance, irs-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–38. doi: 10.1172/JCI59903Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–223. doi: 10.1152/physrev.00063.2017Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–223. doi: 10.1152/physrev.00063.2017Liu D, Yang K, Gu H, Li Z, Wang Y, Wang Y. Predictive effect of triglyceride-glucose index on clinical events in patients with acute ischemic stroke and type 2 diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):280. doi: 10.1186/s12933-022-01704-4Liu D, Yang K, Gu H, Li Z, Wang Y, Wang Y. Predictive effect of triglyceride-glucose index on clinical events in patients with acute ischemic stroke and type 2 diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):280. doi: 10.1186/s12933-022-01704-4Shi W, Xing L, Jing L, Tian Y, Yan H, Sun Q, Dai D, Shi L, Liu S. Value of triglyceride-glucose index for the estimation of ischemic stroke risk: insights from a general population. Nutr Metab Cardiovasc Dis. 2020;30:245–53. doi: 10.1016/j.numecd.2019.09.015Shi W, Xing L, Jing L, Tian Y, Yan H, Sun Q, Dai D, Shi L, Liu S. Value of triglyceride-glucose index for the estimation of ischemic stroke risk: insights from a general population. Nutr Metab Cardiovasc Dis. 2020;30:245–53. doi: 10.1016/j.numecd.2019.09.015Guo Y, Zhao J, Zhang Y, Wu L, Yu Z, He D, Huang H, Qu W, Luo X. Triglyceride glucose index influences platelet reactivity in acute ischemic stroke patients. BMC Neurol. 2021;21(1):409. doi: 10.1186/s12883-021-02443-xGuo Y, Zhao J, Zhang Y, Wu L, Yu Z, He D, Huang H, Qu W, Luo X. Triglyceride glucose index influences platelet reactivity in acute ischemic stroke patients. BMC Neurol. 2021;21(1):409. doi: 10.1186/s12883-021-02443-xChen W, Wang S, Lv W, Pan Y. Causal associations of insulin resistance with coronary artery disease and ischemic stroke: a Mendelian randomization analysis. BMJ Open Diabetes Res Care. 2020;8(1):e001217. doi: 10.1136/bmjdrc-2020-001217Chen W, Wang S, Lv W, Pan Y. Causal associations of insulin resistance with coronary artery disease and ischemic stroke: a Mendelian randomization analysis. BMJ Open Diabetes Res Care. 2020;8(1):e001217. doi: 10.1136/bmjdrc-2020-001217Chu LM, Liu CC, Yeh CC, Chang YC, Hu CJ, Shih CC, Cherng YG, Chen TL, Liao CC. Increased diabetes risk and interaction with social and medical events in patients upon stroke: two nationwide studies. Atherosclerosis. 2017;265:87–92. doi: 10.1016/j.atherosclerosis.2017.08.017Chu LM, Liu CC, Yeh CC, Chang YC, Hu CJ, Shih CC, Cherng YG, Chen TL, Liao CC. Increased diabetes risk and interaction with social and medical events in patients upon stroke: two nationwide studies. Atherosclerosis. 2017;265:87–92. doi: 10.1016/j.atherosclerosis.2017.08.017Hierons SJ, Marsh JS, Wu D, Blindauer CA, Stewart AJ. The interplay between non-esterified fatty acids and plasma zinc and its infl uence on thrombotic risk in obesity and type 2 diabetes. Int J Mol Sci. 2021;22(18). doi: 10.3390/ijms221810140Hierons SJ, Marsh JS, Wu D, Blindauer CA, Stewart AJ. The interplay between non-esterified fatty acids and plasma zinc and its infl uence on thrombotic risk in obesity and type 2 diabetes. Int J Mol Sci. 2021;22(18). doi: 10.3390/ijms221810140Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, Aboyans V, Bäck M, Badimon L, Cosentino F, De Carlo M, Dorobantu M, Harrison DG, Guzik TJ, Hoefer I, Morris PD, Norata GD, Suades R, Taddei S, Vilahur G, Waltenberger J, Weber C, Wilkinson F, Bochaton-Piallat M-L, Evans PC. Endothelial function in cardiovascular medicine: A consensus paper of the European society of cardiology working groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis. Cardiovasc Res. 2021;117(1):29–42. doi: 10.1093/cvr/cvaa085Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, Aboyans V, Bäck M, Badimon L, Cosentino F, De Carlo M, Dorobantu M, Harrison DG, Guzik TJ, Hoefer I, Morris PD, Norata GD, Suades R, Taddei S, Vilahur G, Waltenberger J, Weber C, Wilkinson F, Bochaton-Piallat M-L, Evans PC. Endothelial function in cardiovascular medicine: A consensus paper of the European society of cardiology working groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis. Cardiovasc Res. 2021;117(1):29–42. doi: 10.1093/cvr/cvaa085Muniyappa R, Chen H, Montagnani M, Sherman A, Quon MJ. Endothelial dysfunction due to selective insulin resistance in vascular endothelium: Insights from mechanistic modeling. Am J Physiol Endocrinol Metab. 2020;319(3):E629–e46. doi: 10.1152/ajpendo.00247.2020Muniyappa R, Chen H, Montagnani M, Sherman A, Quon MJ. Endothelial dysfunction due to selective insulin resistance in vascular endothelium: Insights from mechanistic modeling. Am J Physiol Endocrinol Metab. 2020;319(3):E629–e46. doi: 10.1152/ajpendo.00247.2020Potenza AM, Gagliardi S, Nacci C, Carratu RM, Montagnani M. Endothelial dysfunction in diabetes: From mechanisms to therapeutic targets. Curr Medicinal Chem. 2009;16(1):94–112. doi: 10.2174/092986709787002853Potenza AM, Gagliardi S, Nacci C, Carratu RM, Montagnani M. Endothelial dysfunction in diabetes: From mechanisms to therapeutic targets. Curr Medicinal Chem. 2009;16(1):94–112. doi: 10.2174/092986709787002853Den Hartogh DJ, Vlavcheski F, Giacca A, Tsiani E. Attenuation of free fatty acid (Ffa)-induced skeletal muscle cell insulin resistance by resveratrol is linked to activation of ampk and inhibition of mtor and P70 S6k. Int J Mol Sci. 2020;21(14). doi: 10.3390/ijms21144900Den Hartogh DJ, Vlavcheski F, Giacca A, Tsiani E. Attenuation of free fatty acid (Ffa)-induced skeletal muscle cell insulin resistance by resveratrol is linked to activation of ampk and inhibition of mtor and P70 S6k. Int J Mol Sci. 2020;21(14). doi: 10.3390/ijms21144900Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Saccà L, Ferrannini Е. Clustering of insulin resistance with vascular dysfunction and low-grade infl ammation in type 2 diabetes. Diabetes. 2006;55(4):1133–40. doi: 10.2337/diabetes.55.04.06.db051076Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Saccà L, Ferrannini Е. Clustering of insulin resistance with vascular dysfunction and low-grade infl ammation in type 2 diabetes. Diabetes. 2006;55(4):1133–40. doi: 10.2337/diabetes.55.04.06.db051076Hwang DL, Yen CF, Nadler JL. Insulin increases intracellular magnesium transport in human platelets. J Clin Endocrinol Metab. 1993;76(3):549–53. doi: 10.1210/jcem.76.3.8445010Hwang DL, Yen CF, Nadler JL. Insulin increases intracellular magnesium transport in human platelets. J Clin Endocrinol Metab. 1993;76(3):549–53. doi: 10.1210/jcem.76.3.8445010Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24(8):1476–85. doi: 10.2337/diacare.24.8.1476Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24(8):1476–85. doi: 10.2337/diacare.24.8.1476Feske SK. Ischemic stroke. Am J Med. 2021;134(12):1457–64. doi: 10.1016/j.amjmed.2021.07.027Feske SK. Ischemic stroke. Am J Med. 2021;134(12):1457–64. doi: 10.1016/j.amjmed.2021.07.027Di Pino A, DeFronzo RA. Insulin resistance and atherosclerosis: Implications for insulin-sensitizing agents. Endocrine Rev. 2019;40(6):1447–67. doi: 10.1210/er.2018-00141Di Pino A, DeFronzo RA. Insulin resistance and atherosclerosis: Implications for insulin-sensitizing agents. Endocrine Rev. 2019;40(6):1447–67. doi: 10.1210/er.2018-00141Love KM, Liu Z. Dpp4 activity, hyperinsulinemia, and atherosclerosis. J Clin Endocrinol Metab. 2021;106(6):1553–65. doi: 10.1210/clinem/dgab078Love KM, Liu Z. Dpp4 activity, hyperinsulinemia, and atherosclerosis. J Clin Endocrinol Metab. 2021;106(6):1553–65. doi: 10.1210/clinem/dgab078Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, Karagiannis А. Diabetes and lipid metabolism. Hormones. 2018;17(1):61–7. doi: 10.1007/s42000018-0014-8Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, Karagiannis А. Diabetes and lipid metabolism. Hormones. 2018;17(1):61–7. doi: 10.1007/s42000018-0014-8Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238. doi: 10.1016/j.molmet.2021.101238Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238. doi: 10.1016/j.molmet.2021.101238Zabala A, Darsalia V, Lind M, Svensson AM, Franzén S, Eliasson B, Patrone C, Jonsson M, Nyström T. Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2021;20(1):202. doi: 10.1186/s12933-021-01394-4Zabala A, Darsalia V, Lind M, Svensson AM, Franzén S, Eliasson B, Patrone C, Jonsson M, Nyström T. Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2021;20(1):202. doi: 10.1186/s12933-021-01394-4Li S., Yin C., Zhao W., Zhu H., Xu D., Xu Q., Jiao Y., Wang X., Qiao H. Homeostasis model assessment of insulin resistance in relation to the poor functional outcomes in nondiabetic patients with ischemic stroke. Biosci. Rep. 2018;38(3):BSR20180330. doi: 10.1042/BSR20180330Li S., Yin C., Zhao W., Zhu H., Xu D., Xu Q., Jiao Y., Wang X., Qiao H. Homeostasis model assessment of insulin resistance in relation to the poor functional outcomes in nondiabetic patients with ischemic stroke. Biosci. Rep. 2018;38(3):BSR20180330. doi: 10.1042/BSR20180330Jing J., Pan Y., Zhao X., Zheng H., Jia Q., Mi D., Chen W., Li H., Liu L., Wang C., He Y., Wang D., Wang Y., Wang Y. Insulin Resistance and Prognosis of Nondiabetic Patients with Ischemic Stroke: The ACROSS-China Study (Abnormal Glucose Regulation in Patients with Acute Stroke Across China). Stroke. 2017;48(4):887–893. doi: 10.1161/STROKEAHA.116.015613Jing J., Pan Y., Zhao X., Zheng H., Jia Q., Mi D., Chen W., Li H., Liu L., Wang C., He Y., Wang D., Wang Y., Wang Y. Insulin Resistance and Prognosis of Nondiabetic Patients with Ischemic Stroke: The ACROSS-China Study (Abnormal Glucose Regulation in Patients with Acute Stroke Across China). Stroke. 2017;48(4):887–893. doi: 10.1161/STROKEAHA.116.015613Åberg D., Åberg N.D., Jood K., Holmegaard L., Redfors P., Blomstrand C., Isgaard J., Jern C., Svensson J. Homeostasis model assessment of insulin resistance and outcome of ischemic stroke in non-diabetic patients — a prospective observational study. BMC Neurol. 2019;19(1):177. doi: 10.1186/s12883-019-1406-3Åberg D., Åberg N.D., Jood K., Holmegaard L., Redfors P., Blomstrand C., Isgaard J., Jern C., Svensson J. Homeostasis model assessment of insulin resistance and outcome of ischemic stroke in non-diabetic patients — a prospective observational study. BMC Neurol. 2019;19(1):177. doi: 10.1186/s12883-019-1406-3Diener HC, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: Jacc focus seminar. J Am Coll Cardiol. 2020;75(15):1804–18. doi: 10.1016/j.jacc.2019.12.072Diener HC, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: Jacc focus seminar. J Am Coll Cardiol. 2020;75(15):1804–18. doi: 10.1016/j.jacc.2019.12.072Kleindorfer DO, Towfi ghi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith Jr SC, Turan TN, Williams LS. Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American heart Association/American stroke association. Stroke. 2021;52(7):e364–467. doi: 10.1161/str.0000000000000375Kleindorfer DO, Towfi ghi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith Jr SC, Turan TN, Williams LS. Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American heart Association/American stroke association. Stroke. 2021;52(7):e364–467. doi: 10.1161/str.0000000000000375Baden MY, Shan Z, Wang F, Li Y, Manson JE, Rimm EB, Willett WC, Hu FB, Rexrode KM. Quality of plant-based diet and risk of total, ischemic, and hemorrhagic stroke. Neurology. 2021;96(15):e1940–e53. doi: 10.1212/wnl.0000000000011713Baden MY, Shan Z, Wang F, Li Y, Manson JE, Rimm EB, Willett WC, Hu FB, Rexrode KM. Quality of plant-based diet and risk of total, ischemic, and hemorrhagic stroke. Neurology. 2021;96(15):e1940–e53. doi: 10.1212/wnl.0000000000011713Nesti L, Mengozzi A, Tricò D. Impact of nutrient type and sequence on glucose tolerance: Physiological insights and therapeutic implications. Front Endocrinol (Lausanne). 2019;10:144. doi: 10.3389/fendo.2019.00144Nesti L, Mengozzi A, Tricò D. Impact of nutrient type and sequence on glucose tolerance: Physiological insights and therapeutic implications. Front Endocrinol (Lausanne). 2019;10:144. doi: 10.3389/fendo.2019.00144Jeong SH, Joo HJ, Kwon J, Park E-C. Global, regional, and national burden of stroke and its risk factors, 1990-2019: A systematic analysis for the global burden of disease study 2019. Lancet Neurol. 2021;20(10):795–820. doi: 10.1016/s1474-4422(21)00252-0Jeong SH, Joo HJ, Kwon J, Park E-C. Global, regional, and national burden of stroke and its risk factors, 1990-2019: A systematic analysis for the global burden of disease study 2019. Lancet Neurol. 2021;20(10):795–820. doi: 10.1016/s1474-4422(21)00252-0Saunders DH, Sanderson M, Hayes S, Johnson L, Kramer S, Carter DD, Jarvis H, Brazzelli M, Mead GE. Physical fitness training for stroke patients. Cochrane Database Syst Rev. 2020;3(3):Cd003316. doi: 10.1002/14651858.CD003316.pub7Saunders DH, Sanderson M, Hayes S, Johnson L, Kramer S, Carter DD, Jarvis H, Brazzelli M, Mead GE. Physical fitness training for stroke patients. Cochrane Database Syst Rev. 2020;3(3):Cd003316. doi: 10.1002/14651858.CD003316.pub7Whillier S. Exercise and insulin resistance. Adv Exp Med Biol. 2020;1228:137–50. doi: 10.1007/978-981-15-1792-1_9Whillier S. Exercise and insulin resistance. Adv Exp Med Biol. 2020;1228:137–50. doi: 10.1007/978-981-15-1792-1_9Hallschmid M. Intranasal insulin. J Neuroendocrinol (2021) 33(4):e12934. doi: 10.1111/jne.12934Hallschmid M. Intranasal insulin. J Neuroendocrinol (2021) 33(4):e12934. doi: 10.1111/jne.12934Craft S, Raman R, Chow TW, Rafi i MS, Sun CK, Rissman RA, Donohue MC, Brewer JB, Jenkins C, Harless K, Gessert D, Aisen PS. Safety, effi cacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: A randomized clinical trial. JAMA Neurol. 2020;77(9):1099–109. doi: 10.1001/jamaneurol.2020.1840Craft S, Raman R, Chow TW, Rafi i MS, Sun CK, Rissman RA, Donohue MC, Brewer JB, Jenkins C, Harless K, Gessert D, Aisen PS. Safety, effi cacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: A randomized clinical trial. JAMA Neurol. 2020;77(9):1099–109. doi: 10.1001/jamaneurol.2020.1840Huang SS, Lu YJ, Huang JP, Wu YT, Day YJ, Hung LM. The essential role of endothelial nitric oxide synthase activation in insulin-mediated neuroprotection against ischemic stroke in diabetes. J Vasc Surg. 2014;59(2):483–91. doi: 10.1016/j.jvs.2013.03.023Huang SS, Lu YJ, Huang JP, Wu YT, Day YJ, Hung LM. The essential role of endothelial nitric oxide synthase activation in insulin-mediated neuroprotection against ischemic stroke in diabetes. J Vasc Surg. 2014;59(2):483–91. doi: 10.1016/j.jvs.2013.03.023Lebovitz HE. Thiazolidinediones: The forgotten diabetes medications. Curr Diabetes Rep. 2019;19(12):151. doi: 10.1007/s11892-019-1270-yLebovitz HE. Thiazolidinediones: The forgotten diabetes medications. Curr Diabetes Rep. 2019;19(12):151. doi: 10.1007/s11892-019-1270-yKernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams Jr HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med (2016) 374(14):1321–31. doi: 10.1056/NEJMoa1506930Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams Jr HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med (2016) 374(14):1321–31. doi: 10.1056/NEJMoa1506930Lee M., Saver J.L., Liao H.W., Lin C.H., Ovbiagele B. Pioglitazone for Secondary Stroke Prevention : A Systematic Review and Meta-Analysis. Stroke. 2017;48(2):388–393. doi: 10.1161/STROKEAHA.116.013977Lee M., Saver J.L., Liao H.W., Lin C.H., Ovbiagele B. Pioglitazone for Secondary Stroke Prevention : A Systematic Review and Meta-Analysis. Stroke. 2017;48(2):388–393. doi: 10.1161/STROKEAHA.116.013977Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2019;10(10):Cd010693. doi: 10.1002/14651858.CD010693.pub5Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2019;10(10):Cd010693. doi: 10.1002/14651858.CD010693.pub5Sharma S, Nozohouri S, Vaidya B, Abbruscato T. Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke. Life Sci. 2021;274:119343. doi: 10.1016/j.lfs.2021.119343Sharma S, Nozohouri S, Vaidya B, Abbruscato T. Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke. Life Sci. 2021;274:119343. doi: 10.1016/j.lfs.2021.119343Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–56. doi: 10.1016/j.cmet.2018.03.001Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–56. doi: 10.1016/j.cmet.2018.03.001Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, Langhans W, Krause E, de Kloet A, Gribble FM, Reimann F, Rinaman L, de Lartigue G, Trapp S. Central and peripheral glp-1 systems independently suppress eating. Nat Metab. 2021;3(2):258–73. doi: 10.1038/s42255-021-00344-4Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, Langhans W, Krause E, de Kloet A, Gribble FM, Reimann F, Rinaman L, de Lartigue G, Trapp S. Central and peripheral glp-1 systems independently suppress eating. Nat Metab. 2021;3(2):258–73. doi: 10.1038/s42255-021-00344-4Love KM, Liu J, Regensteiner JG, Reusch JEB, Liu Z. Glp-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. J Diabetes. 2020;12(7):488–98. doi: 10.1111/1753-0407.13045Love KM, Liu J, Regensteiner JG, Reusch JEB, Liu Z. Glp-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. J Diabetes. 2020;12(7):488–98. doi: 10.1111/1753-0407.13045Hanssen R, Kretschmer AC, Rigoux L, Albus K, Edwin Thanarajah S, Sitnikow T, Melzer C, Cornely OA, Brüning JC, Tittgemeyer M. Glp-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. Mol Metab. 2021;45:101163. doi: 10.1016/j.molmet.2021.101163Hanssen R, Kretschmer AC, Rigoux L, Albus K, Edwin Thanarajah S, Sitnikow T, Melzer C, Cornely OA, Brüning JC, Tittgemeyer M. Glp-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. Mol Metab. 2021;45:101163. doi: 10.1016/j.molmet.2021.101163Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–13. doi: 10.1016/s2213-8587(17)30412-6Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–13. doi: 10.1016/s2213-8587(17)30412-6Maskery MP, Holscher C, Jones SP, Price CI, Strain WD, Watkins CL, Werring DJ, Emsley HC. Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke : A systematic scoping review. J Cereb Blood Flow Metab. 2021;41(1):14–30. doi: 10.1177/0271678x20952011Maskery MP, Holscher C, Jones SP, Price CI, Strain WD, Watkins CL, Werring DJ, Emsley HC. Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke : A systematic scoping review. J Cereb Blood Flow Metab. 2021;41(1):14–30. doi: 10.1177/0271678x20952011

The authors declare that there are no conflicts of interest present.